Retinal surgery volume rose 22.3 percent year over year.
The system is the first non-laser automated cataract capsulotomy device to gain US approval.
At least four companies are in various stages of developing these lenses.
Copycat drugmakers no longer have to wait until after approval to give notice to biologic producer.
Commissioner told US lawmakers that adding two generic options nearly halves cost of branded drug.
The medical association adopted a policy calling for drugmakers to include the suggested retail prices of drugs in consumer ads.
The proposed development would accommodate about 1,500 employees.
The filtering system is designed to deliver preservative-free drops from preserved multidose products.
The surgeon owned a private medical practice for almost 20 years.
The company plans to submit a new drug application for Roclatan in the first half of 2018.
The implantable, permanent sensor measures intraocular pressure throughout the day in glaucoma patients.
The drug’s FDA target action date was Sept. 8, 2017.
The company agreed to pay $2.15 million for future royalties on the technology, which Ellex acquired in 2014.
jCell uses retinal progenitor cells to rescue diseased retinal cells.
The division could be worth $2 billion, according to reports.
The company said a trial is underway for a presbyopia-correcting version.
The cataract equipment market will total $1.55 billion in 2017
Global revenues for ophthalmic lasers will total $422 million in 2017.
Novartis owns the Pataday brand, acquiring it with its purchase of Alcon.
His early work at Harvard helped lay the foundation for LASIK refractive surgery.
You are not currently logged in.
©2017 Market Scope
Lost your Password